232 related articles for article (PubMed ID: 34768993)
1. Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients.
Pawłowska A; Kwiatkowska A; Suszczyk D; Chudzik A; Tarkowski R; Barczyński B; Kotarski J; Wertel I
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768993
[TBL] [Abstract][Full Text] [Related]
2. Prognostic and Clinical Value of Interleukin 6 and CD45
Wertel I; Suszczyk D; Pawłowska A; Bilska M; Chudzik A; Skiba W; Paduch R; Kotarski J
J Immunol Res; 2020; 2020():1715064. PubMed ID: 33062717
[TBL] [Abstract][Full Text] [Related]
3. Clinical Value of the PD-1/PD-L1/PD-L2 Pathway in Patients Suffering from Endometriosis.
Suszczyk D; Skiba W; Zardzewiały W; Pawłowska A; Włodarczyk K; Polak G; Tarkowski R; Wertel I
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36232911
[TBL] [Abstract][Full Text] [Related]
4. [Programmed cell death protein 1 and its ligands regulate immune balance in allergic rhinitis].
Wen SL; Li F; Zhao F; Zuo JJ; Deng YQ; Zhang W; Tao ZZ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2020 Apr; 55(4):384-390. PubMed ID: 32306637
[No Abstract] [Full Text] [Related]
5. Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1.
Okła K; Rajtak A; Czerwonka A; Bobiński M; Wawruszak A; Tarkowski R; Bednarek W; Szumiło J; Kotarski J
J Transl Med; 2020 Jun; 18(1):220. PubMed ID: 32487171
[TBL] [Abstract][Full Text] [Related]
6. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
7. Ras association domain family protein 1a hypermethylation and PD-L1 expression in ovarian cancer: A retrospective study of 112 cases.
Zhu X; Yang H; Lang J; Zhang Y
Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():103-108. PubMed ID: 31242460
[TBL] [Abstract][Full Text] [Related]
8. The role of PD-1/PD-Ls in the pathogenesis of IgG4-related disease.
Zhang X; Lu H; Peng L; Zhou J; Wang M; Li J; Liu Z; Zhang W; Zhao Y; Zeng X; Lu L
Rheumatology (Oxford); 2022 Feb; 61(2):815-825. PubMed ID: 33930105
[TBL] [Abstract][Full Text] [Related]
9. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
11. Programmed Death-1 Receptor (PD-1) as a Potential Prognosis Biomarker for Ovarian Cancer Patients.
Pawłowska A; Suszczyk D; Tarkowski R; Paduch R; Kotarski J; Wertel I
Cancer Manag Res; 2020; 12():9691-9709. PubMed ID: 33116828
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of PD-L2 expression in patients with oral squamous cell carcinoma-A comparison to the PD-L1 expression profile.
Weber M; Wehrhan F; Baran C; Agaimy A; Büttner-Herold M; Kesting M; Ries J
Cancer Med; 2019 Mar; 8(3):1124-1134. PubMed ID: 30659749
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of programed death ligand-1 and ligand-2 co-expression in salivary gland carcinomas.
Nakano T; Takizawa K; Uezato A; Taguchi K; Toh S; Masuda M
Oral Oncol; 2019 Mar; 90():30-37. PubMed ID: 30846173
[TBL] [Abstract][Full Text] [Related]
14. A Clinicopathological and Prognostic Analysis of PD-L2 Expression in Surgically Resected Primary Lung Squamous Cell Carcinoma.
Matsubara T; Takada K; Azuma K; Takamori S; Toyokawa G; Haro A; Osoegawa A; Tagawa T; Kawahara A; Akiba J; Okamoto I; Nakanishi Y; Oda Y; Hoshino T; Maehara Y
Ann Surg Oncol; 2019 Jun; 26(6):1925-1933. PubMed ID: 30815803
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: A systematic review and meta-analysis.
Huang LJ; Deng XF; Chang F; Wu XL; Wu Y; Diao QZ
Medicine (Baltimore); 2018 Oct; 97(43):e12858. PubMed ID: 30412078
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and Prognostic Analysis of PD-L1 and PD-L2 Expression in Surgically Resected Primary Tongue Squamous Cell Carcinoma.
Furukawa K; Kawasaki G; Yoshida T; Umeda M
Anticancer Res; 2021 Jan; 41(1):101-111. PubMed ID: 33419803
[TBL] [Abstract][Full Text] [Related]
17. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
18. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility.
Santoso B; Sa'adi A; Dwiningsih SR; Tunjungseto A; Widyanugraha MYA; Mufid AF; Rahmawati NY; Ahsan F
Am J Reprod Immunol; 2020 Oct; 84(4):e13296. PubMed ID: 32593225
[TBL] [Abstract][Full Text] [Related]
19. Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancer.
Ojalvo LS; Thompson ED; Wang TL; Meeker AK; Shih IM; Fader AN; Cimino-Mathews A; Emens LA
Hum Pathol; 2018 Apr; 74():135-147. PubMed ID: 29288043
[TBL] [Abstract][Full Text] [Related]
20. Hantavirus-Driven PD-L1/PD-L2 Upregulation: An Imperfect Viral Immune Evasion Mechanism.
Raftery MJ; Abdelaziz MO; Hofmann J; Schönrich G
Front Immunol; 2018; 9():2560. PubMed ID: 30559738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
